Investor FAQs

Aegerion was founded in 2005. The company went public in 2010.

Aegerion Pharmaceuticals common stock is traded on the NASDAQ Global Market under the ticker symbol "AEGR."

00767E 102

101 Main Street, Suite 1850,
Cambridge, MA 02142

Aegerion Pharmaceuticals does not offer a direct stock purchase plan. Shares of the Company should be purchased through a broker.

Aegerion Pharmaceuticals does not currently pay dividends.

Registrar and Transfer Company
Investor Relations Department
10 Commerce Drive
Cranford, NJ 07016
(800) 368-5948

To replace lost certificates, contact the transfer agent: www.rtco.com, a free web tool for shareholders.

To change address, contact the transfer agent: www.rtco.com, a free web tool for shareholders.

Aegerion Pharmaceuticals fiscal year is based on the calendar year.

First Quarter ends 3/31, Second Quarter ends 6/30, Third Quarter ends 9/30 and Fourth Quarter ends 12/31.

Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on the development and commercialization of novel life-altering therapeutics for rare and often fatal diseases. The Company's lead product, lomitapide, is a first-in-class, small molecule, oral therapy to treat severe lipid disorders for an orphan patient population. Lomitapide has demonstrated a significant lowering of both bad cholesterol (LDL-C) and triglyceride (TG) levels in patients with a rare form of hypercholesterolemia. Aegerion submitted an NDA to the FDA, and an MAA to the EMA, in the first quarter of 2012. The Company also plans to initiate a clinical program to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia (FC).

Please submit your question using the form below. * Required fields

Name *
Email *
Subject *
Comments *
Type in number *
	This helps Aegerion Pharmaceuticals, Inc. prevent automated submissions.